Phenotypes associated with this allele

• Allele Symbol: Nod1^tm1Inoh
• Allele Name: targeted mutation 1, Naohiro Inohara
• Allele ID: MGI:2674231
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Nod1^tm1Inoh/Nod1^tm1Inoh	involves: 129P2/OlaHsd * C57BL/6	MGI:2674233
cx2	Nod1^tm1Inoh/Nod1^tm1Inoh Nod2^tm1Flv/Nod2^tm1Flv	involves: 129 * 129P2/OlaHsd * C57BL/6	MGI:3831400

Genotype
MGI:2674233

hm1

• Allelic Composition: Nod1^tm1Inoh/Nod1^tm1Inoh
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

abnormal immune system physiology ( J:118808 )

• 16 hours after KF1B administration, mutants show absence of neutrophil recruitment whereas immune cell recruitment is induce in wild-type

abnormal macrophage physiology ( J:118808 , J:132126 )

• bone marrow-derived mouse macrophages do not show increased LPS-induced CCL2 secretion with KF1B treatement (J:118808)

• bone marrow derived macrophages produce less IL-6 and TNF when cultured in the presence of L. monocytogenes (J:132126)

• in macrophages pre-treated with TLR ligands (i.e. "tolerized"), macrophages produce significantly less inflammatory cytokines upon incubation with L. monocytogenes than controls that were LPS pre-treated (J:132126)

abnormal cytokine secretion ( J:118808 )

• KF1B administration does not induce cytokine production in mutants in contrast to wild-type

abnormal chemokine secretion ( J:118808 )

• enhancement of LPS-induced secretion of chemokine ligand 2/MCP-1 (CCL2/MCP-1) into the serum by KF1B is absent in mutants compared to wild-type

• intranasal and oral KF1B administration does induce CCL2 secretion into the serum in mutants similar to wild-type

decreased interleukin-6 secretion ( J:132126 )

• bone marrow derived macrophages secrete 73% the amount of IL-6 as wild-type controls in response to culturing with L. monocytogenes

• a similar relative reduction is observed when macrophages are pre-treated with LPS prior to L. monocytogenes incubation

decreased tumor necrosis factor secretion ( J:132126 )

• bone marrow derived macrophages secrete 83% the amount of TNF as wild-type controls in response to culturing with L. monocytogenes

• TNF secretion is 55% that of controls when macrophages are pre-treated with LPS prior to L. monocytogenes incubation

hematopoietic system

abnormal macrophage physiology ( J:118808 , J:132126 )

• bone marrow-derived mouse macrophages do not show increased LPS-induced CCL2 secretion with KF1B treatement (J:118808)

• bone marrow derived macrophages produce less IL-6 and TNF when cultured in the presence of L. monocytogenes (J:132126)

• in macrophages pre-treated with TLR ligands (i.e. "tolerized"), macrophages produce significantly less inflammatory cytokines upon incubation with L. monocytogenes than controls that were LPS pre-treated (J:132126)

Genotype
MGI:3831400

cx2

• Allelic Composition: Nod1^tm1Inoh/Nod1^tm1Inoh; Nod2^tm1Flv/Nod2^tm1Flv
• Genetic Background: involves: 129 * 129P2/OlaHsd * C57BL/6

immune system

abnormal macrophage physiology ( J:132126 )

• bone marrow derived macrophages produce less IL-6 and TNF when cultured in the presence of L. monocytogenes

• in macrophages pre-treated with TLR ligands (i.e. "tolerized"), macrophages produce significantly less inflammatory cytokines upon incubation with L. monocytogenes than controls that were LPS pre-treated

decreased interleukin-6 secretion ( J:132126 )

• bone marrow derived macrophages secrete 40% the amount of IL-6 as wild-type controls due in response to culturing with L. monocytogenes

• IL-6 secretion is 7% that of controls when macrophages are pre-treated with LPS prior to L. monocytogenes incubation

• IL-6 secretion is 18% that of controls when macrophages are pre-treated with E. Coli prior to L. monocytogenes incubation

decreased tumor necrosis factor secretion ( J:132126 )

• bone marrow derived macrophages secrete 56% the amount of TNF as wild-type controls in response to culturing with L. monocytogenes

• TNF secretion is 13% that of controls when macrophages are pre-treated with LPS prior to L. monocytogenes incubation

• TNF secretion is 26% that of controls when macrophages are pre-treated with E. Coli prior to L. monocytogenes incubation

increased susceptibility to bacterial infection ( J:132126 )

• there is an approximately 5-fold higher number of bacterial colony-forming units in the liver and spleen than in wild-type mice 2 days after infection with L. monocytogenes

• when mice are pre-treated with LPS before infection, bacterial load in the liver and spleen is about 50- to 70- fold higher than in wild-type mice

• mutant mice that are pretreated with LPS before L. monocytogenes infection have a survival rate of about 35% compared to controls that have a 100% survival rate

• these LPS pre-treated mice have a higher number of liver microabcesses than controls after L. monocytogenes infection that were LPS pre-treated

hematopoietic system

abnormal macrophage physiology ( J:132126 )

• bone marrow derived macrophages produce less IL-6 and TNF when cultured in the presence of L. monocytogenes

• in macrophages pre-treated with TLR ligands (i.e. "tolerized"), macrophages produce significantly less inflammatory cytokines upon incubation with L. monocytogenes than controls that were LPS pre-treated